The neurorestorative effects of exogenous neurturin (NTN) delivered directly into the putamen via multiport catheters were studied in 10 MPTP-lesioned rhesus monkeys expressing stable parkinsonism. The parkinsonian animals were blindly assigned to receive coded solutions containing either vehicle (n = 5) or NTN (n = 5, 30 µg/day). Both solutions were coinfused with heparin using convection-enhanced delivery for 3 months. The NTN recipients showed a significant and sustained behavioral improvement in their parkinsonian features during the treatment period, an effect not seen in the vehicle-treated animals. At study termination, locomotor activity levels were increased by 50% in the NTN versus vehicle recipients. Also, DOPAC levels were significantly increased by 150% ipsilateral (right) to NTN infusion in the globus pallidus, while HVA levels were elevated bilaterally in the NTN-treated animals by 10% on the left and 67% on the right hemisphere. No significant changes in DA function were seen in the putamen. Volumetric analysis of putamenal NTN labeling showed between-subject variation, with tissue distribution ranging from 214 to 744 mm 3 , approximately equivalent to 27-93% of area coverage. Our results support the concept that intraparenchymal delivery of NTN protein may be effective for the treatment of PD. More studies are needed to determine strategies that would enhance tissue distribution of exogenous NTN protein, which could contribute to optimize its trophic effects in the parkinsonian brain.
INTRODUCTION
Based on the promising studies of the chronic effects of intraparenchymal GDNF in nonhuman primate models of PD, a series of studies was conducted in PD pa-Neurotrophic factors are proteins with enormous therapeutic potential in the treatment of neurodegenerative tients. However, translational studies from the laboratory to the clinic for the treatment of advanced PD have diseases such as Parkinson's disease (PD). Neurotrophic factors may not only slow or halt the degeneration of been difficult. On one hand, two independent open-label phase I studies have reported marked functional im-substantia nigra dopamine (DA) neurons due to their neuroprotective properties, but may also enhance the provements in a total of 15 advanced PD patients receiving intraputamenal infusion of GDNF for several months function of residual DA neurons or even repair and restore function to injured DA neurons. Over the last de- (5, 17, 23, 28) . On the other hand, a randomized, blinded multicenter phase II trial conducted in 34 advanced PD cade, we and others have focused on the effects of glial cell line-derived neurotrophic factor (GDNF) on mid-patients, of which 17 received intraputamenal GDNF infusion for 6 months, did not achieve its primary study brain DA neurons (3, 13) . Using computer-controlled infusion pumps, our group has demonstrated that chronic endpoint (i.e., 25% change from baseline in off-medication motor scores) (16, 20) . There were major technical administration of GDNF into the lateral ventricle, putamen, or substantia nigra promotes restoration of the ni-differences between these clinical trials in catheter design and infusion protocols (27) , which may have re-grostriatal DA system and significantly improves motor functions in rhesus monkeys with neural deficits model-sulted in variable distribution of GDNF in the brain parenchyma and likely contributed to the different study ing PD (4,7). 374 GRONDIN ET AL. outcomes (25) . Although there is no evidence of serious MATERIALS AND METHODS GDNF-induced adverse effects in patients at this time, Animals all trials testing for human recombinant GDNF were Ten female rhesus monkeys (Macaca mulatta) rangstopped due to safety concerns, including but not limited ing in age from 14 to 19 years old and weighing between to the presence of neutralizing antibodies to GDNF in 6 and 10 kg were used for this study. The animals were some patients (16, 28) .
maintained on a 12-h light/12-h dark cycle and single-As an alternative to GDNF, other members of the housed with individual access to an adjacent activity GDNF family ligands have been tested for their theramodule. The diet consisted of certified nonhuman pripeutic potential, such as neurturin (NTN), which shares mate Harlan Teklad chow, supplemented daily in midabout 42% similarity with mature GDNF (15) . NTN proafternoon with fresh fruit or vegetables. Water was tein has been shown to promote the survival and moravailable ad libitum. All procedures were approved by phological differentiation of several different neuronal the University of Kentucky Animal Care and Use Comsubtypes in vitro, including midbrain DA neurons (11, mittee and were conducted in the Laboratory Animal 32). Along the same lines, intrastriatal injections of Facilities of the University of Kentucky, which are fully NTN protein in rodent models of PD have demonstrated accredited by the Association for Assessment and Acneuroprotective and neuroregenerative effects on DA nicreditation of Laboratory Animal Care. Veterinarians grostriatal function (21, 24) . In nonhuman primates, the skilled in the health care and maintenance of nonhuman intracranial delivery of adeno-associated type 2 viral primates supervised all animal care. vector encoding human NTN (AAV2-NTN) has been reported to prevent toxin-induced motor disability follow-Surgical Procedures ing injection into the striatum (14) . While gene delivery MPTP Administration. The animals received right allows for bilateral administration of the trophic factor intracarotid artery infusions of 1-methyl-4-phenyl-1,2, into multiple sites and long-term transgene expression 3,6-tetrahydropyridine (MPTP; 0.8-0.9 mg per animal) with no need for chronically implanted hardware, the to induce continuously expressed parkinsonian features development of techniques for determining and controlas per procedures previously described (22). Briefly, folling dosing and timing remain difficult. In addition, the lowing ligation of the external carotid artery, a volume direct delivery of NTN protein into the brain has not of 4-4.5 ml of MPTP solution (0.2 mg/ml) was delivpreviously been tested in a nonhuman primate model of ered at a rate of 1 ml/min using a 25-gauge butterfly PD, and whether this approach could be used as an alterneedle bent at the tip to a slight angle and inserted in native to viral vector delivery of NTN is unknown.
retrograde direction to the blood flow through the com-Here we report the results of an experiment designed mon carotid artery. The incision was then closed as per to blindly assess the restorative effects of exogenous normal surgical procedures. Following MPTP adminis-NTN protein chronically delivered to the nonhuman pritration, all animals developed stable parkinsonian feamate nigrostriatal DA system. To promote tissue distritures as assessed using a clinical rating scale adapted for bution, NTN was coadministered with heparin similar to rhesus monkeys (22). Hamilton et al. (9) and infused using convection-enhanced delivery via computer-controlled pumps and indwelling Pump and Catheter Placement. NTN or its vehicle was chronically delivered via intraparenchymal multi-catheters. While targeting of multiple sites is difficult, programmable pumps can dispense drugs in a variety of port catheters and programmable infusion pumps (Medtronic Inc., Minneapolis, MN). The anesthetized animals ways. The rate and timing of delivery (e.g., continuous or timed infusion) are noninvasively programmed through (1-3% isoflurane) were placed in a stereotaxic head frame in a ventral-lateral position. Using sterile proce-an external computer, allowing a greater range of flexibility and control in administrating trophic factors at a dures, an incision was made through the scalp and the skin and muscles overlying the skull were reflected. desired dose into specific brain sites. Locomotor activity was measured using automated video tracking software, Then a small hole was drilled in the skull directly over the right putamen as per MRI-guided stereotaxic proce-and movement dysfunctions characteristic of PD were rated using a nonhuman primate clinical rating scale.
dures and the overlying meninges were punctured to expose the surface of the brain for insertion of the catheter. Following 3 months of infusion treatment, the animals were euthanized and their brains recovered for quantita-
The catheter (1 mm O.D., Model 8770IP24A) is designed so that six laser holes are placed radially on a tive post mortem analyses, including neurochemical measurements of DA function and unbiased stereologi-longitudinal distance of 3 mm over each 90°of the catheter's circumference, for a total of 24 laser holes (0.0375 cal cell counting. Our results support the concept that intraparenchymal delivery of NTN protein may be effec-mm in diameter). Once positioned, the catheter was then connected via flexible polyurethane tubing to a Synchro tive for the treatment of PD.
Med II programmable infusion pump (model 8637-20)
cage background, which is then defined as all other pixels. The resultant x-y coordinates extracted as a function subcutaneously implanted in the lateral abdominal region (6). After completion of the procedures, the inci-of time are used for calculating the movement pattern during the observation period. These coordinates were sions were sutured over the exposed areas per normal procedures. Each animal was given buprenorphine (0.01 subsequently related to actual spatial measures by calibrating the software to the cage width, so that the dis-mg/kg, IM) and monitored until it was ambulatory.
tance traveled by the animal was calculated in centime-Drug Treatment ters instead of pixels. The animals were rank ordered into two groups of Post Mortem Analyses five animals as per their parkinsonian features and blind-Tissue Biopsies. At the end of the study, each animal ly assigned to receive either vehicle (10 mM NaAcetate, was deeply anesthetized with sodium pentobarbital pH 5.5, 4% Mannitol) or NTN (0.2 mg/ml). Coded solu-(ϳ15 mg/kg, IV) and transcardially perfused with 4-6 tions containing NTN or its vehicle were provided by L of heparinized ice-cold saline. Then the brain was re-Rinat Neuroscience, Inc. (South San Fransico, CA). To moved quickly and sectioned into 4-mm coronal slabs, enhance tissue distribution, the pumps were programmed rostral to the midbrain, using an ice-cold rhesus monkey to deliver brief pulses of 25 µl over short 2-min periods brain mold. The coronal slabs were then placed at (12.5 µl/min), four times a day. In addition, the mini-−20°C, so that multiple tissue punches could be taken mum basal infusion rate, which is necessary to keep the bilaterally from frozen 4-mm thick coronal tissue secpumps operating properly between each bolus, was set tions using a 14-gauge biopsy needle in the putamen (n = at 0.033 µl/min (2 µl/h) for a total infusion volume of 15 punches per side) and globus pallidus (n = 5 punches 150 µl per day. This represents a dose of 30 µg NTN per side). All punches were rapidly transferred to predelivered daily for 3 months. To reduce the binding of weighed storage tubes, weighed, and stored at −80°C NTN to heparin binding sites in the extracellular matrix until assayed for DA, homovanillic acid (HVA), and and promote tissue distribution, NTN was coinfused 3,4-dihydroxy-phenylacetic acid (DOPAC) measurewith heparin (9) as per the following ratio: 0.6 units of ments by HPLC with electrochemical detection (2,7). heparin per 1 µg of NTN. Each pump was refilled monthly using aseptic procedures.
Immunohistochemistry and Quantitative Morphology. In parallel, the midbrain was taken out as a block and Behavioral Measurements postfixed in 4% paraformaldehyde in phosphate buffer (pH 7.4) along with all 4-mm coronal slabs rostral to Rating Scale. The animals were videotaped using the midbrain for quantitative immunocytochemistry of standardized procedures (22, 30) . Changes in motor substantia nigra DA neurons and volume of NTN distrifunctions were assessed using our previously published bution in the brain. As detailed elsewhere (4), 40-µmnonhuman primate parkinsonian scale, patterned after thick coronal sections were cut on a frozen sliding mithe human Unified Parkinson's Disease Rating Scale crotome through the substantia nigra and processed for (22). Behavioral parameters associated with motor funcimmunohistochemical staining for tyrosine hydroxylase tion were scored from coded videotapes from 0 (normal) (TH, monoclonal antibody, 1:1000; Chemicon Internato 3 (severe disability) in the following categories: rigidtional Inc., Temecula, CA). The number of TH+ midity, bradykinesia, posture, balance, tremor, and hand brain dopaminergic neurons was estimated bilaterally dexterity. Rigidity was defined as a decrease in limb using an optical fractionator method for unbiased stereoextension and/or use. Motor dysfunctions were rated in logical cell counting (1, 4) . In addition, a series of 40half-point increments by a single experienced rater µm-thick coronal sections was cut on a frozen sliding blinded to the treatment administered to the animals. In microtome through the striatum and immunostained for addition, the tapes were analyzed to determine if the ani-NTN (1:500 goat anti-human neurturin antibody; AF387, mals displayed side effects from the treatment, including R&D). The volume of distribution of NTN was quantivomiting, stereotypies, and dyskinesia.
fied using three-dimensional reconstruction software EthoVision. As described elsewhere (30) , distance (Bioquant, Nashville, TN) on every 12th section through traveled (cm) was quantified from the same videotapes the brain (4, 25) . Quantitative morphology and volumetusing a commercially available video tracking system ric analysis was performed by a single investigator (EthoVision Pro 2.3, Noldus Technology, Asheville, blinded to the experimental conditions. NC). This automated method relies on determining the Statistics position of the center of mass of the animal in the cage using a gray scale detection method by calibrating the The cumulative parkinsonian scores of the vehicle and NTN recipients were analyzed using a nonparamet-software to distinguish the dark-colored animal from the ric Friedman test followed with a post hoc analysis using a Dunn's Multiple Comparison Test, when appropriate. Between-group comparisons were conducted using a nonparametric Mann-Whitney Test (one-tailed). Locomotor activity levels were analyzed using a two-factor repeated-measures analysis of variance (ANOVA) with treatment as between-subjects factor and week of treatment as within-subjects factor, followed by Newman-Keuls post hoc comparisons. Pre-MPTP locomotor activity levels are shown for comparison, but were not included in the analysis. For each hemisphere, independent sample t-tests (one-tailed) were used to estimate differences in DA, DOPAC, or HVA levels and nigral cell counts between animals in the control and NTN treatment groups. A value of p < 0.05 was considered significant in all analyses. ing), stereotypic movements, dyskinesias, self-mutilation (e.g., hair loss, bite marks), or other psychotic behavior (e.g., apparently following imaginary objects or As seen in Figure 2 , distance traveled (cm) measured not demonstrating awareness of humans in the room) pre-MPTP administration was comparable between the throughout the study. Also, no significant changes in two treatment groups. Following the MPTP administrabody weight were measured during the study in either tion, locomotor activity levels significantly decreased by the vehicle-or NTN-treated animals. However, one of ϳ50% in both treatment groups compared to pre-MPTP the NTN recipients (#P680) unexpectedly died overactivity levels (one-tailed, paired t-tests). No significant night, 8 weeks posttreatment, and was excluded from changes in locomotor activity levels were seen in the the analysis for this reason. An autopsy revealed that vehicle-treated animals over the course of the 3-month this animal died from a massive brain hemorrhage study ( Fig. 2A) . A slight increase in distance traveled around the catheter implantation site of undetermined was noted up to 6 weeks postoperatively, an effect poscause.
sibly due to catheter placement into the brain paren-Motor Functions chyma that eventually subsided to return to prevehicle treatment levels by the end of the study. In contrast, As described above, standardized videotaping procedures were conducted pre-and posttreatment to evaluate locomotor activity levels were progressively and significantly increased in the NTN recipients by up to 78% at changes in motor functions from coded videotapes. Prior to chronic infusion into the right putamen, both vehicle-week 10 posttreatment compared to post-MPTP baseline levels. By the end of the study, locomotor activity levels and NTN-treated animals were given comparable cumulative parkinsonian scores of 7.0 ± 0.26 and 6.25 ± in the NTN-treated animals were still 50% higher versus post-MPTP baseline levels (Fig. 2B ). 0.59 points, respectively, as assessed using our rating scale adapted to monkeys (Fig. 1) . No significant changes Neurochemistry in parkinsonian features were seen in the vehicle-treated animals over the 12-week infusion period ( Fig. 1, open At the end of the 3-month infusion study, multiple tissue punches were taken bilaterally in the putamen (n = circles). In contrast, the parkinsonian scores progressively improved in the NTN recipients over the course 15 punches per side) and globus pallidus (n = 5 punches per side). All punches were assayed for changes in DA, of the study, reaching a significant 20% improvement in motor scores by the 10th week of NTN infusion (Fig. 1 , HVA, and DOPAC between animals in the control and NTN treatment groups. MPTP administration caused a filled circles). This level of improvement was maintained through the 12th week of treatment.
marked decrease in DA and DA metabolite levels. In the vehicle-only recipients at the termination of the study, Locomotor activity levels were quantified from the same videotapes over 60-min-long observation periods tissue levels of DA, DOPAC, and HVA in the right putamen were significantly decreased by >99%, >99% and using the automated video-tracking system, EthoVision. 92%, respectively, versus the levels on the left side of trend was seen for DA due to variability within the NTN-treated animals (p = 0.06). Additionally, a more the brain (Table 1) . No significant differences were seen in DA, DOPAC, or HVA putamenal tissue levels marginal but significant increase in HVA levels (10%) was also measured in the globus pallidus contralateral between vehicle-and NTN-treated animals, either contralateral (left) or ipsilateral (right) to NTN infusion (left) to NTN infusion. (Table 1) .
Quantitative Morphology and Volume of Distribution MPTP also decreased pallidal levels of DA and related metabolites in the vehicle-treated animals. When Consistent with decreased DA function in the putamen and globus pallidus ( Table 1 , and Fig. 3) , the num-compared to tissue levels in the left pallidum, DA (137 ± 8 vs. 30 ± 5), DOPAC (50 ± 6 vs. 11 ± 3), and HVA ber of TH+ neurons in the right substantia nigra of vehicle recipients was significantly reduced to 13% of that (8,049 ± 237 vs. 1,277 ± 172) were significantly decreased by 78%, 78%, and 84%, respectively, in the found in the contralateral (left) hemisphere (Table 2) . However, quantitative morphology showed no signifi-right pallidum of the vehicle recipients (Fig. 3 ). In contrast to the putamen, significant increases in DOPAC cant differences in the number of dopaminergic neurons expressing TH between NTN and vehicle recipients in (150%) and HVA (67%) tissue levels were measured in the globus pallidus ipsilateral (right) to NTN infusion the substantia nigra ( Table 2) . Tissue distribution of NTN in the brain was quanti-compared to vehicle treatment (Fig. 3) . A nonsignificant fied from immunocytochemically stained sections using three-dimensional reconstruction software. As seen in Figure 4 , the volume of distribution (V d ) of NTN in the putamen varied over threefold between animals ranging 4 . Volume of tissue distribution in the putamen of four markedly reduced the levels of DA, HVA, and DOPAC. In MPTP-lesioned monkeys receiving NTN via multiport catheter contrast, DOPAC levels were significantly increased 150% ipfor 12 weeks. Volumetric analysis of putamenal NTN labeling silateral (right) to NTN infusion (B). Also, HVA levels were showed between-subject variation, with tissue distribution elevated bilaterally in the NTN-treated animals by 10% on the ranging from 214 to 744 mm 3 . The mean volume of distribuleft and 67% on the right hemisphere (C). Values are extion achieved with GDNF delivered in the rhesus monkey pupressed as ng/g wet weight of tissue. **p < 0.01, left versus tamen using similar multiport catheters is shown for compariright brain-vehicle treatment (paired t-tests); #p < 0.05, vehison (4) . The dotted line indicates the estimated volume of the cle versus NTN-same side (unpaired t-tests).
entire putamen (800 mm 3 ). from a low 214 mm 3 in one animal to 744 mm 3 in the tion of NTN protein promoted axonal sprouting in the globus pallidus (24). It may be that changes in extrastri-monkey with the highest volume of distribution (mean V d ± SEM = 461 ± 112 mm 3 ), roughly equivalent to 27- atal DA function and metabolism such as those seen here in the globus pallidus are more important than stria-93% area coverage (mean % ± SEM = 58 ± 14%) based on an estimated putamenal volume of 800 mm 3 . In prior tal tissue levels of DA for promoting improvements in motor function. In contrast to our prior studies on GDNF studies (4), the volume of distribution quantified by immunocytochemistry for chronically infused GDNF using (1, 7) , quantitative morphology showed no significant differences in the number of dopaminergic neurons ex-similar multiport catheters and delivery method was found to be twofold greater than that achieved with pressing TH between NTN and vehicle recipients in the substantia nigra. Similarly, no significant differences in NTN, ranging from 647 to 990 mm 3 (mean V d ± SEM = 854 ± 81 mm 3 ).
the survival of nigral TH+ neurons were found between vehicle controls and NTN-treated parkinsonian rats fol-DISCUSSION lowing injection of NTN into the striatum 12 weeks after 6-hydroxydopamine administration (21) . While no in-The 10 animals in this study were long-term stable hemiparkinsonian monkeys. The animals were implanted crease in nigral cell number was seen in the NTN-treated animals herein, it is possible that NTN may be acting by with a multiport catheter into the right putamen, which was connected to a computer-controlled pump to chroni-upregulating DA uptake and/or release in the substantia nigra as seen before in rhesus monkeys with GDNF (8). cally deliver the trophic factor NTN for 3 months at a dose of 30 µg per day. One neurturin-treated animal Additional studies would be needed to determine if NTN can upregulate DA uptake and release in the nigrostriatal unexpectedly died from a brain hemorrhage of undetermined cause after 8 weeks of treatment. Chronic infu-system as a mechanism to promote improvement in motor function. sion of heparin may have been a contributing factor. This is the first case of death by brain hemorrhage re-Although statistically significant, the effects of NTN on parkinsonian features (20% reduction) reported here ported in all our studies using over 50 indwelling intraventricular or intraparenchymal catheters for the chronic following single-site, unilateral delivery into the putamen were more modest compared to those obtained with infusion of a trophic factor (4, 7, 8, 18) .
Nonetheless, the results from our study indicate that GDNF in our prior studies. To put that in perspective, we have previously reported that bilateral, chronic intra-exogenous NTN exerts some restorative effects in MPTPlesioned rhesus monkeys modeling PD and extend prior putamenal infusion of 22.5 µg per day of GDNF promotes a 40% improvement in parkinsonian scores in reports demonstrating that the delivery of AAV2-NTN to the nigrostriatal system can restore motor function for MPTP-lesioned hemiparkinsonian rhesus monkeys using a similar delivery method (7). Also, in a recent study up to 10 months and prevent nigral cell loss in parkinsonian monkeys (14) . In aged monkeys, AAV2-NTN re- (14) , AAV2-NTN-treated monkeys showed a mean 88% reduction in the parkinsonian features at 10 months post-sulted in increased striatal [ 18 F]fluorodopa uptake and enhanced TH+ fibers in the striatum (10). Consistent treatment into multiple sites: caudate (n = 2 injections), putamen (n = 3 injections), and substantia nigra (n = 1 with a gradual increase in general locomotor activity over the course of the study described here, the parkin-injection). One possibility to explain these differences in the percentage change in antiparkinsonian benefit is that sonian scores were significantly improved in the NTN recipients. In accordance with our prior studies with multiple site delivery of trophic factor may promote greater improvement in motor function than single site GDNF (7), HVA (bilaterally) and DOPAC tissue levels were increased in the globus pallidus between vehicle-delivery. Along the same lines, dosing of exogenous NTN (30 µg/day) may not have been optimal in our and NTN-treated animals, whereas no significant differences were seen in DA or DA metabolite tissue levels study considering that NTN binds preferentially to GFR-α2 receptors of which very few are found in the nigro-in the putamen. These data support the hypothesis that behavioral improvements are not always associated with striatal system (26,31). Like GDNF, NTN also binds to GFR-α1 receptors through which it may exert its action changes in striatal DA levels (3) . The effects of NTN on pallidal DA function are of importance considering that in the striatum but to a lesser extent than GDNF. Additional dose-response studies would be needed to address the globus pallidus receives dopaminergic input from the substantia nigra and is involved in regulating motor this question. Tissue distribution of trophic factor is a critical vari-functions by sending outputs to the motor cortex via the thalamus (29) . Similar to GDNF in rodents (12), NTN able to achieve optimal effects on DA function and promote behavioral improvement in rhesus monkeys mod-has been shown to be transported anterogradely from the striatum to the globus pallidus in nonhuman primates eling PD. In a prior study, the volume of distribution of GDNF in the trophic factor recipients significantly (10, 14) . In rodent models of PD, intrastriatal administra-
